Related Experiment Video

Updated: Aug 12, 2026

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice
08:15

Cardiac Pressure-Volume Loop Analysis Using Conductance Catheters in Mice

Published on: September 17, 2015

Hemodynamic and metabolic effects of enalapril in patients with heart failure

S G Chrysant, S Gollub, M I Dunn

    Clinical Cardiology
    |November 1, 1985
    PubMed

    Insights

    Enalapril improved congestive heart failure (CHF) outcomes, including exercise tolerance and heart function, without adverse effects. This study suggests enalapril is a safe and effective addition to conventional CHF treatments.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Congestive heart failure (CHF) affects millions globally, necessitating effective treatment strategies.
    • Conventional treatments for CHF often require adjunct therapies to improve patient outcomes.

    Purpose of the Study:

    • To evaluate the efficacy and safety of enalapril as an add-on therapy for patients with congestive heart failure (CHF).
    • To assess the impact of enalapril on cardiac function, exercise capacity, and metabolic parameters in CHF patients.

    Main Methods:

    • A double-blind, placebo-controlled study involving 14 patients with New York Heart Association class II-III CHF.
    • Patients received conventional treatment plus either enalapril or placebo for 14 weeks.
    • Evaluations included treadmill tests, nuclear scans for ejection fraction, cardiothoracic ratio, Yale Scale scores, and metabolic studies.

    Main Results:

    • Enalapril significantly decreased arterial pressure and cardiothoracic ratio, while increasing ejection fraction.
    • Both enalapril and placebo improved treadmill performance and Yale Scale scores.
    • No significant adverse metabolic or clinical effects were observed with enalapril.

    Conclusions:

    • Enalapril is a beneficial ancillary agent for conventional congestive heart failure (CHF) treatment.
    • Enalapril's therapeutic effects are attributed to afterload and preload reduction.
    • Enalapril demonstrated safety, tolerability, and a prolonged duration of action in this patient cohort.

    More Related Videos

    Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS08:12

    Invasive Hemodynamic Monitoring of Aortic and Pulmonary Artery Hemodynamics in a Large Animal Model of ARDS

    Published on: November 26, 2018

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

    Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

    Published on: May 26, 2022

    Related Concept Videos

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

    Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

    Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...